Most Read Articles
5 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 5 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 3 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.

Re-emergence of pertussis in the post-vaccination era: A Malaysian perspective

06 Nov 2019
Q1. Could you please describe the current state of pertussis epidemiology,both local and globally?
Pertussis is a worldwide epidemic infectious disease, without breaks occurring every 2–5 years. In the prevaccine era, the incidence and case-fatality rates of pertussis were very high, especially among children aged younger than 5 years. The diphtheria-tetanus-pertussis combination vaccine (ie, DTP vaccine), which has been part of the World Health Organisation (WHO)’s Expanded Programme on Immunisation since 1974, has resulted in a dramatic decline in pertussis incidence and mortality. Without vaccination, the disease would have resulted in more than 1.3 million deaths globally in the year 2001.1

According to WHO, the global vaccination coverage of the DTP3 vaccine in 2013 was estimated at 84%2; in the same year, pertussis was reported to have caused as many as 63,000 deaths in children aged younger than 5 years worldwide.1 In 2018, WHO estimated that about 86% of infants (or 116.3 million infants) worldwide received DTP3, but approximately 19.4 million infants did not have access to routine immunisation services, including the DTP3 vaccine,during the same period.3

In Malaysia, the incidence of pertussis was less than 1/100,000 population prior to 2012, with no deaths in the preceding decade 4; however, the incidence of pertussis increased almost 22-fold from 41 cases in 2010 to 892 cases in 2018.5 According to the Ministry of Health (MOH), there were 22 deaths from pertussis in 2018 alone and 19 of the affected children had no prior history of vaccination.6

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 5 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 3 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.